<DOC>
	<DOCNO>NCT00921310</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) combination temsirolimus pemetrexed , well response rate . The start dose ( Dose Level 1 ) schedule pemetrexed 500 mg/m^2 give every 3 week start dose ( Dose Level 1 ) temsirolimus 15 mg give weekly 3 week , complete 1 cycle . In subsequent cohort , dose escalate de-escalated . Enrollment cohort base toxicity experience dose level .</brief_summary>
	<brief_title>Temsirolimus Pemetrexed Recurrent Refractory Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>- To determine maximum tolerate dose ( MTD ) temsirolimus could administer weekly combination pemetrexed . - To determine dose-limiting toxicity ( DLT ) temsirolimus pemetrexed well toxicity combination therapy . - To describe response rate combination patient relapsed/refractory non-small cell lung cancer ( NSCLC ) . - To describe phospho-Akt phospho-S6 level circulate mononuclear cell treatment . - To determine response rate patient NSCLC treat temsirolimus pemetrexed . - To evaluate progression-free survival patient NSCLC treat temsirolimus pemetrexed . - To determine one-year survival rate patient NSCLC treat temsirolimus pemetrexed . - To describe phospho-Akt phospho-S6 level circulate mononuclear cell treatment .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients must histologically cytologically confirm diagnosis NSCLC . Patients must nonsquamous histology . Patients must measurable disease ( RECIST criterion ) , define least one lesion accurately measure least one dimension ( long diameter record ) ≥20 mm conventional technique ≥10 mm spiral CT scan . Patients may fail least one prior platinumbased therapy NSCLC candidate firstline therapy advanced disease deem ineligible receive platinumbased chemotherapy opinion treat physician ( e.g. , Eastern Cooperative Oncology Group ( ECOG ) performance status 2 , age ≥ 70 , chronic medical condition ) . Patients must least 4 week chemotherapy , biological therapy , major surgery , investigative therapy must recover toxicity . Patients must least 2 week prior radiation therapy must recover associated toxicity ( exception alopecia ) . Patients must least 3 week immunosuppressive therapy ( except corticosteroid use antiemetic ) . Age ≥18 year . Because dose adverse event data currently available use pemetrexed combination temsirolimus patient &lt; 18 year age , child exclude study . ECOG performance status 02 . Patients must normal organ marrow function define : hemoglobin ≥9.0 g/dL absolute neutrophil count ≥1,500/mcL platelets ≥100,000/mcL total bilirubin ≤1.5 mg/dL aspartate aminotransferase ( AST ) ( SGOT ) / alanine aminotransferase ( ALT ) ( SGPT ) ≤2.5 X institutional upper limit normal OR ≤5 X institutional upper limit normal enzyme abnormality due liver metastasis creatinine &lt; 2.0 mg/dL AND/OR creatinine clearance ≥60 mL/min/1.73 m2 patient creatinine level institutional normal serum cholesterol &lt; 350 mg/dL triglyceride &lt; 300 mg/dL The effect pemetrexed temsirolimus develop human fetus recommend therapeutic dose unknown . For reason antifolate antineoplastic agent well therapeutic agent use trial know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability patient ( legally authorize representative applicable ) understand willingness sign write informed consent document . Both men woman member race ethnic group eligible trial . Patients previous treatment pemetrexed . Patients may receive investigational agent . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , clinically significant hepatic renal disease neuropathy great grade 2 . Symptomatic brain metastasis Presence thirdspace fluid ( pleural effusion , ascites etc . ) uncontrolled drainage . History allergic reaction attribute compound similar chemical biologic composition temsirolimus , metabolite ( include sirolimus ) , component , and/or polysorbate 80 , agent use study . Known hypersensitivity macrolide antibiotic . Patients psychiatric illness/social situation would limit compliance study requirement premedications dexamethasone , folic acid vitamin B12 . Patients inability discontinue nonsteroidal antiinflammatory drug ( NSAIDS ) . Patients take anticonvulsant medication ( Carbamezapine , phenytoin , fosphenytoin , phenobarbital ) . Patients take antiarrhythmic medication ( amiodarone , diltiazem quinidine ) . Patients may take medication know inhibitor CYP3A4 ( carbamezapine , phenytoin , phenobarbital , rifampin , St. John 's wort ) . Use inducer CYP3A4 discourage specifically prohibit . Dexamethasone chronic medication discourage . Pregnant woman exclude study pemetrexed antifolate antineoplastic drug potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother pemetrexed , breastfeed discontinue mother treated pemetrexed . These potential risk may also apply agent use study . Patients know concomitant genetic acquire immunosuppressive disease exclude . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction pemetrexed temsirolimus . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Temsirolimus pemetrexed recurrent refractory NSCLC</keyword>
</DOC>